A “healthy brain” is a brain in its neural dynamic stable state. Deviation from the neural cohesion and symmetry is usually a result of the brain’s exposure to trauma, either physical traumatic brain injury or psychogenic. Such trauma can trigger sleep disturbance, insomnia, post traumatic stress disorder, anxiety, depression, bipolar disorder and other mental disorders which are often subsequently self-medicated by those affected, compounding the changes in the brain’s physiological condition and negatively impacting an individual’s behavior.
In addition to behavioral evaluations, many scientific tests are available to directly measure the brain’s physiological properties in terms of its health condition. Studies with co-registered assessments of Positron Emission Tomography (PET) scan, Magnetic Resonance Imaging (MRI) and Electroencephalogram (EEG) have shown that the brain metabolic rate is determined, to a great extent, by the levels of symmetry in its underlying electrical activities. Electromagnetic Brain Pulsing (EMBP) is a new, advanced and patented technology.
Pulsed Electromagnetic Field Therapy
The essence of this electromagnetic therapy is identifying the patient’s physiological brain condition through quantitative analyses, and then, delivering a customized, magnetic pulse-matching, electromagnetic stimulation to normalize the human brain condition.
EMBP is a noninvasive, out-patient, physiological treatment procedure delivered through a mechanism called “neural modulation.” EMBP consists of three steps as it is delivered to a patient:
- Recording the patient’s EEG at rest
- Analyzing the EEG data by comparing them with a normative database, using an Artificial Intelligence (AI) process, to identify a patient’s characteristic alpha pattern
- Delivering a pulse generator sequence that is customized according to an individual patient’s neurological pattern with its unique frequency distribution. The magnetic field treatment’s intent is to help restore the individual’s default brain state.
In the past 15 years, a growing body of literature following this theory has been published, dozens of patents have been granted, and the principles within the theory have been adopted by many other clinical research groups, manufacturers and clinics. In contrast to all of the existing brain stimulation technologies, EMBP has shown equal or higher efficacy, depending on clinical conditions, and a much lower rate of adverse effect.
Repetitive Transcranial Magnetic Stimulation Treatment
Above is an illustration of the journey of pioneer Yi Jin, MD, leading him to the latest advancement: EMBP brain-wave-guided transcranial magnetic stimulation treatment. Yi Jin, MD, currently serves as Director of Neuromodulation at the Center for NeuroRestoration at the University of Southern California (USC). Through his academic research and clinical applications over the past 30 years, EMBP has been developed in combination with his knowledge of the first principles of thermodynamics and information processing of the brain, and his clinical experiences in psychiatry.
PTSD Clinical Trial Results
The following executive summary describes a randomized, double-blind, placebo-controlled study of the treatment of Veterans diagnosed with PTSD, using Dr. Jin’s first patented neuromodulation protocol published in the journal, Trauma Monthly, November 2015.
A 64% drop in the PTSD score was achieved in 4 weeks. Response is durable and dramatic, indicating an effective neuromodulation therapy for PTSD.
Eighty-six (86) combat Veterans diagnosed with PTSD were included in the study. The study was designed with two treatment phases: 1) double-blind and 2) open-label.
All patients were randomly assigned into one of two study groups (Treatment or Control (sham)) and were treated for two weeks during phase 1 followed by two more weeks of open-label trial. Clinical symptoms were evaluated using the PTSD Checklist – Military (PCL-M) at pre-treatment, weeks 2 and 4 of treatment, and 8 weeks post-treatment.
Average pre-treatment PCL-M score was 65.7 in the treatment group and 65.4 in the control group. Two-week post-treatment PCL-M in the treatment group saw a 47.4 percent reduction (23.3 point reduction in symptoms severity), and in the control group a 28.9 percent (14.0 point reduction, P < 0.01). Both groups saw continued improvement during open-label treatment, with average PCL-M reduction of 64 percent at week 4. No adverse events (seizures, neurologic deficit, worsening of pretreatment condition) were reported.